More recently, a pooled analysis of the German CLL Study Group (GCLLSG) considering frontline treatment trials with both CIT and pathway inhibitors, including Bruton tyrosine kinase (BTK) and BCL2 inhibitors, has documented a 3% prevalence of RS transformation among 2975 CLL patients monitored after their enrolment in clinical trials, recruited from 1999 to 2016, with a median observation time of 53 months [15]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.